Milestone for Biopharmaceuticals in China
As one of the world’s largest biopharmaceutical producers, Boehringer Ingelheim is China’s first international provider of biopharmaceutical contract manufacturing solutions with all-round services, including process development and product supply for clinical trials and market, to its clients in China and all over the world.
Boehringer Ingelheim started to become involved in a reform of the Chinese MAH/Contract Manufacturing model in 2014, which enables a new regulatory pathway to authorize a third party in manufacturing biopharmaceutical products for drug authorization holders.
Now Boehringer Ingelheim BioXcellence™ manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Boehringer Ingelheim BioXcellence™ offers reliable world-class biopharmaceuticals contract development and manufacturing services to the pharmaceutical and biotechnology industry.
Boehringer Ingelheim BioXcellence™ welcomes your inquiries, questions and feedback.